DARA BioSciences Reports on SurgiVision's Filing of a Registration Statement With the Securities and Exchange Commission for an Initial Public Offering (IPO)

DARA has Been an Investor in SurgiVision Since 2004

        Print
| Source: DARA BioSciences, Inc.

RALEIGH, N.C., Dec. 23, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), announced today that SurgiVision, Inc., a privately held company of which DARA owns approximately 2,200,000 shares and warrants to purchase an additional 405,000 shares, has filed a registration statement with the Securities and Exchange Commission (SEC) covering the initial public offering of its common stock. SurgiVision's registration statement, which was filed on December 23, 2009, may be accessed through the SEC's website at www.sec.gov.

For more information about SurgiVision, Inc., please visit: http://www.surgivision.com.

About DARA BioSciences, Inc.

DARA BioSciences, Inc. is a Raleigh, North Carolina based development-stage biopharmaceutical company that acquires promising therapeutic small molecules and develops them through proof of concept in humans for subsequent sale or out-licensing to mid and large pharmaceutical companies. Presently DARA has two drug candidates with cleared INDs (Investigational New Drug) Applications from the US FDA. One of these drug candidates, KRN5500, has successfully completed a Phase 2a clinical trial treating cancer patients for neuropathic pain. It has a portfolio of drug candidates for neuropathic pain, type 2 diabetes, and psoriasis. For more information please contact the Company at 919-872-5578 or visit our web site at www.darabio.com.

Cameron Associates, Inc.
Kevin McGrath
212.245.4577